Revolution Medicines and Moderna prove that high-risk bets on undruggable targets can finally work - here's what it means for biotech investors and pharma execs.

New research warns that leaning on generative AI at work can weaken the moral and contextual judgment managers need most.

After 15 years, Tim Cook hands Apple to John Ternus - here's how he turned a $350B company into a $4.6T juggernaut.

A Business Insider reporter attends the sold-out event and finds a crowd desperate for shortcuts, while Johnson himself admits the ultimate irony.

Industry groups say the proposed fee could hit budget travelers hardest, threatening a key segment of the country's tourism recovery.

President Trump doubled down on tariffs, telling U.S. businesses to stop importing Canadian goods and crediting his trade policy for reviving Ford and GM.

Analysts say the worst of the commercial property slump may be passing, yet highly leveraged owners still face a tough refinancing path ahead.

A fragmented creative industry is leaving regional hits on the table - collaboration could turn them into a global cultural force.

A failed late-stage heart study triggered a swift market punishment, forcing investors and boards to reset timelines and risk.